Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1994 Sep;97(3):510–516. doi: 10.1111/j.1365-2249.1994.tb06118.x

Expression of p75 chain of IL-2 receptor in the early immunological reconstitution after allogeneic bone marrow transplantation.

P Comoli 1, R Maccario 1, D Montagna 1, M Labirio 1, M Zecca 1, R Clementi 1, F Bonetti 1, F Locatelli 1
PMCID: PMC1534849  PMID: 8082308

Abstract

Expression of p55 and p75 chains of IL-2 receptor (IL-2R) on the surface of both T and natural killer (NK) circulating lymphocytes was investigated in 14 paediatric patients given allogeneic bone marrow transplantation (BMT) from HLA-identical sibling or partially matched family donors. IL-2-induced proliferative and cytotoxic responses were also studied and all analysis was performed within 45 days from transplant. We found that, early after transplant, the percentage of p55+ and of p75+ peripheral blood lymphocytes (PBL) was not significantly different in patients who had received HLA-identical BMT (p55+ 8.04 +/- 4.87%; p75+ 28.27 +/- 18.85%) compared with healthy controls (p55+ 7.26 +/- 6.17%; p75+ 19.42 +/- 10.49%), while recipients of T cell-depleted marrow included a remarkably high percentage (76-90%) of p75+ PBL, which were mostly CD3- and co-expressed CD56 molecule. Comparable values of p55+ lymphocytes were observed in all patients and controls. However, in contrast to the other two groups, in recipients of T cell-depleted BMT the majority of these cells co-expressed p75 chain and CD56 antigen. IL-2-induced proliferation and lymphokine-activated killer (LAK) activity were detectable in all patients, and their values did not correlate with expression of p55 or p75 chains. Our data suggest that expansion of NK subsets expressing IL-2R chains after T cell-depleted BMT may be related to early reconstitution of natural immunity in the presence of allogeneic stimuli.

Full text

PDF
510

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson K. Reconstruction of the haemopoietic and immune systems after marrow transplantation. Bone Marrow Transplant. 1990 Apr;5(4):209–226. [PubMed] [Google Scholar]
  2. Caligiuri M. A., Zmuidzinas A., Manley T. J., Levine H., Smith K. A., Ritz J. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med. 1990 May 1;171(5):1509–1526. doi: 10.1084/jem.171.5.1509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ceredig R., Lowenthal J. W., Nabholz M., MacDonald H. R. Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells. Nature. 1985 Mar 7;314(6006):98–100. doi: 10.1038/314098a0. [DOI] [PubMed] [Google Scholar]
  4. Ciccone E., Pende D., Viale O., Than A., Di Donato C., Orengo A. M., Biassoni R., Verdiani S., Amoroso A., Moretta A. Involvement of HLA class I alleles in natural killer (NK) cell-specific functions: expression of HLA-Cw3 confers selective protection from lysis by alloreactive NK clones displaying a defined specificity (specificity 2). J Exp Med. 1992 Oct 1;176(4):963–971. doi: 10.1084/jem.176.4.963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Foa R., Fierro M. T., Raspadori D., Bonferroni M., Cardona S., Guarini A., Tos A. G., di Celle P. F., Cesano A., Matera L. Lymphokine-activated killer (LAK) cell activity in B and T chronic lymphoid leukemia: defective LAK generation and reduced susceptibility of the leukemic cells to allogeneic and autologous LAK effectors. Blood. 1990 Oct 1;76(7):1349–1354. [PubMed] [Google Scholar]
  6. Glucksberg H., Storb R., Fefer A., Buckner C. D., Neiman P. E., Clift R. A., Lerner K. G., Thomas E. D. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974 Oct;18(4):295–304. doi: 10.1097/00007890-197410000-00001. [DOI] [PubMed] [Google Scholar]
  7. Gottschalk L. R., Bray R. A., Kaizer H., Gebel H. M. Two populations of CD56 (Leu-19)+/CD16+ cells in bone marrow transplant recipients. Bone Marrow Transplant. 1990 Apr;5(4):259–264. [PubMed] [Google Scholar]
  8. Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982 Jun 1;155(6):1823–1841. doi: 10.1084/jem.155.6.1823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Habu S., Okumura K., Diamantstein T., Shevach E. M. Expression of interleukin 2 receptor on murine fetal thymocytes. Eur J Immunol. 1985 May;15(5):456–460. doi: 10.1002/eji.1830150508. [DOI] [PubMed] [Google Scholar]
  10. Hardt C., Diamantstein T., Wagner H. Developmentally controlled expression of IL 2 receptors and of sensitivity to IL 2 in a subset of embryonic thymocytes. J Immunol. 1985 Jun;134(6):3891–3894. [PubMed] [Google Scholar]
  11. Jacobs R., Stoll M., Stratmann G., Leo R., Link H., Schmidt R. E. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood. 1992 Jun 15;79(12):3239–3244. [PubMed] [Google Scholar]
  12. Jenkinson E. J., Kingston R., Owen J. J. Importance of IL-2 receptors in intra-thymic generation of cells expressing T-cell receptors. Nature. 1987 Sep 10;329(6135):160–162. doi: 10.1038/329160a0. [DOI] [PubMed] [Google Scholar]
  13. Lanier L. L., Spits H., Phillips J. H. The developmental relationship between NK cells and T cells. Immunol Today. 1992 Oct;13(10):392–395. doi: 10.1016/0167-5699(92)90087-N. [DOI] [PubMed] [Google Scholar]
  14. Lotzová E., Savary C. A., Herberman R. B. Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol. 1987 Apr 15;138(8):2718–2727. [PubMed] [Google Scholar]
  15. Lum L. G. The kinetics of immune reconstitution after human marrow transplantation. Blood. 1987 Feb;69(2):369–380. [PubMed] [Google Scholar]
  16. Lum L. G., Ueda M. Immunodeficiency and the role of suppressor cells after human bone marrow transplantation. Clin Immunol Immunopathol. 1992 May;63(2):103–109. doi: 10.1016/0090-1229(92)90001-5. [DOI] [PubMed] [Google Scholar]
  17. Maccario R., Nespoli L., Mingrat G., Vitiello A., Ugazio A. G., Burgio G. R. Lymphocyte subpopulations in the neonate: identification of an immature subset of OKT8-positive, OKT3-negative cells. J Immunol. 1983 Mar;130(3):1129–1131. [PubMed] [Google Scholar]
  18. Montagna D., Maccario R., Ugazio A. G., Mingrat G., Burgio G. R. Natural cytotoxicity in the neonate: high levels of lymphokine activated killer (LAK) activity. Clin Exp Immunol. 1988 Jan;71(1):177–181. [PMC free article] [PubMed] [Google Scholar]
  19. Montagna D., Moretta A., Marconi M., Mingrat G., Gasparoni A., Giarola M., Maccario R. In vivo activated cord blood lymphocytes express high affinity interleukin-2 receptor: evaluation of their responsiveness to in vitro stimulation with recombinant interleukin-2. Biol Neonate. 1992;62(6):385–394. doi: 10.1159/000243896. [DOI] [PubMed] [Google Scholar]
  20. Montgomery R. A., Dallman M. J. Analysis of cytokine gene expression during fetal thymic ontogeny using the polymerase chain reaction. J Immunol. 1991 Jul 15;147(2):554–560. [PubMed] [Google Scholar]
  21. Moretta L., Ciccone E., Moretta A., Höglund P., Ohlén C., Kärre K. Allorecognition by NK cells: nonself or no self? Immunol Today. 1992 Aug;13(8):300–306. doi: 10.1016/0167-5699(92)90042-6. [DOI] [PubMed] [Google Scholar]
  22. Oshimi K., Oshimi Y., Akutsu M., Takei Y., Saito H., Okada M., Mizoguchi H. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood. 1986 Oct;68(4):938–948. [PubMed] [Google Scholar]
  23. Piantelli M., Larocca L. M., Aiello F. B., Maggiano N., Carbone A., Ranelletti F. O., Musiani P. Proliferation of phenotypically immature human thymocytes with and without interleukin 2 receptors. J Immunol. 1986 May 1;136(9):3204–3210. [PubMed] [Google Scholar]
  24. Plum J., De Smedt M. Differentiation of thymocytes in fetal organ culture: lack of evidence for the functional role of the interleukin 2 receptor expressed by prothymocytes. Eur J Immunol. 1988 May;18(5):795–799. doi: 10.1002/eji.1830180521. [DOI] [PubMed] [Google Scholar]
  25. Raulet D. H. Expression and function of interleukin-2 receptors on immature thymocytes. Nature. 1985 Mar 7;314(6006):101–103. doi: 10.1038/314101a0. [DOI] [PubMed] [Google Scholar]
  26. Rosenberg S. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst. 1985 Oct;75(4):595–603. [PubMed] [Google Scholar]
  27. Shimonkevitz R. P., Husmann L. A., Bevan M. J., Crispe I. N. Transient expression of IL-2 receptor precedes the differentiation of immature thymocytes. Nature. 1987 Sep 10;329(6135):157–159. doi: 10.1038/329157a0. [DOI] [PubMed] [Google Scholar]
  28. Siegel J. P., Sharon M., Smith P. L., Leonard W. J. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science. 1987 Oct 2;238(4823):75–78. doi: 10.1126/science.3116668. [DOI] [PubMed] [Google Scholar]
  29. Smith K. A. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169–1176. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  30. Teshigawara K., Wang H. M., Kato K., Smith K. A. Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med. 1987 Jan 1;165(1):223–238. doi: 10.1084/jem.165.1.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Toribio M. L., Gutiérrez-Ramos J. C., Pezzi L., Marcos M. A., Martínez C. Interleukin-2-dependent autocrine proliferation in T-cell development. Nature. 1989 Nov 2;342(6245):82–85. doi: 10.1038/342082a0. [DOI] [PubMed] [Google Scholar]
  32. Tsudo M., Goldman C. K., Bongiovanni K. F., Chan W. C., Winton E. F., Yagita M., Grimm E. A., Waldmann T. A. The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. Proc Natl Acad Sci U S A. 1987 Aug;84(15):5394–5398. doi: 10.1073/pnas.84.15.5394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Tsudo M., Kozak R. W., Goldman C. K., Waldmann T. A. Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9694–9698. doi: 10.1073/pnas.83.24.9694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Tuckett I. L. THREE MAGNET CASES WITH SOME UNUSUAL FEATURES. Br J Ophthalmol. 1918 Jun;2(6):329–332. doi: 10.1136/bjo.2.6.329. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Velardi A., Varese P., Grossi C. E., Albi N., Dembech C., Terenzi A., Moretta L., Grignani F., Martelli M. F., Mingari M. C. Cytolytic function of clonable T cells after human bone marrow transplantation. Blood. 1990 Mar 15;75(6):1364–1369. [PubMed] [Google Scholar]
  36. Voltarelli J. C., Stites D. P. Immunological monitoring of bone marrow transplantation. Diagn Immunol. 1986;4(4):171–193. [PubMed] [Google Scholar]
  37. Voss S. D., Sondel P. M., Robb R. J. Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R. J Exp Med. 1992 Aug 1;176(2):531–541. doi: 10.1084/jem.176.2.531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. von Boehmer H., Crisanti A., Kisielow P., Haas W. Absence of growth by most receptor-expressing fetal thymocytes in the presence of interleukin-2. Nature. 1985 Apr 11;314(6011):539–540. doi: 10.1038/314539a0. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES